Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor...
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
About this item
Full title
Author / Creator
Publisher
Durham: Research Square
Journal title
Language
English
Formats
Publication information
Publisher
Durham: Research Square
Subjects
More information
Scope and Contents
Contents
Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although osimertinib is more effective than the first-generation EGFR-TKIs used for first-line treatment, its efficacy with respect to lo...
Alternative Titles
Full title
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2539363948
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2539363948
Other Identifiers
DOI
10.21203/rs.3.rs-19425/v4
How to access this item
https://www.proquest.com/docview/2539363948?pq-origsite=primo&accountid=13902
